Gufic Biosciences Limited (GUFICBIO.BO)
Gufic Biosciences Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Mumbai, MA, IN. The stock last traded at $421.20, down 2.29% on the session, giving a market capitalisation of $42.22B. Its beta of -0.05 implies it has historically moved less than the broad market.
Gufic Biosciences Limited is a pharmaceutical enterprise engaged in the global development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), generic medications, and associated services. The company's extensive international presence spans India, Africa, Asia, Europe, Australia, North America, South America, and other global regions. Its production capabilities encompass APIs and bulk drug substances, including compounds for antifungals, anesthetics, immunosuppressants, and key antifungal intermediates. Additionally, Gufic Biosciences specializes in creating lyophilized injectable products across therapeutic areas such as antibiotics, antifungals, cardiology, infertility, antivirals, and proton-pump inhibitors. The firm's comprehensive portfolio also features pharmaceutical brands like Spark, Criti Care, Criticare Life, and Ferticare, alongside offerings in herbal medicine, aesthetic dermatology (aesthaderm), gufic stridden, and personal care products. These varied products are supplied to major hospital networks and a broad spectrum of medical facilities. Established in 1970, Gufic Biosciences Limited has its headquarters in Mumbai, India.
Gufic Biosciences Limited is most often compared with the following Healthcare names: